Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in Neisseria gonorrhoeae, Hawaii, USA


During 2016, eight Neisseria gonorrhoeae isolates from 7 patients in Hawaii were resistant to azithromycin; 5 had decreased in vitro susceptibility to ceftriaxone. Genomic analysis demonstrated a distinct phylogenetic clade when compared with local contemporary strains. Continued evolution and widespread transmission of these strains might challenge the effectiveness of current therapeutic options.

Neisseria gonorrhoeae is a sexually transmitted pathogen that has progressively developed resistance to the antimicrobial agents recommended for treatment (1). Third-generation cephalosporins are among the last class of antimicrobial agents that are still effective, and ceftriaxone is the foundation of treatment options recommended by the United States (2) and other countries. The diminished cache of drugs to treat gonorrhea has led most countries to recommend a combination of ceftriaxone and azithromycin in an attempt to ensure effective therapy and slow the emergence of resistance by decreasing the likelihood that a N. gonorrhoeae isolate would survive concomitant exposure to 2 antimicrobial agents with distinct mechanisms of action (2). However, sporadic treatment failures have been reported (2), and gonorrhea is considered a global health concern by the World Health Organization and the Centers for Disease Control and Prevention (CDC) because of the few remaining treatment options.

Surveillance for antimicrobial susceptibility of N. gonorrhoeae was established by the CDC in the United States in 1986 as penicillin and tetracycline resistance was becoming widespread. The CDC Gonococcal Isolate Surveillance Project (GISP; Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention) collects ≈5,000 isolates per year from men with urethritis seeking care at sexually transmitted disease clinics across the United States and assesses the isolates for antimicrobial susceptibility (3). The findings are used by CDC to formulate national treatment recommendations and develop research and disease intervention priorities. Ceftriaxone remains highly effective in treating gonorrhea in the United States; 99.9% of isolates were inhibited by <0.125 µg/mL in 2014 (4). However, the percentage of isolates with decreased azithromycin susceptibility (azithromycin MIC ≥ 2 µg/mL) rose sharply from 0.6% in 2013 to 2.5% in 2014. Fortunately, none of the 2014 isolates demonstrated clinical resistance or decreased susceptibility to both azithromycin and ceftriaxone.

The Hawaii Department of Health (HDOH) State Laboratories Division maintains nucleic acid amplification, culture, and antimicrobial drug susceptibility testing by Etest for N. gonorrhoeae. During 2016, the HDOH and CDC became aware of several N. gonorrhoeae isolates with high-level resistance to azithromycin and decreased susceptibility to ceftriaxone in Hawaii as a result of routine laboratory testing and jointly initiated an enhanced laboratory investigation of the isolates.

The Study

The HDOH confirmed the identification of 61 isolates of N. gonorrhoeae, collected during February 2016–May 2016, and antimicrobial drug susceptibility testing was performed on all of them. Isolates were identified as N. gonorrhoeae by using the API NH test kit (bioMérieux, Marcy l’Etoile, France), and the MICs for azithromycin, ceftriaxone, and cefixime was assessed by Etest for (bioMérieux) on GC II agar supplemented with 1% IsoVitaleX (bioMérieux). Etest carried out at the HDOH State Laboratories Division found that 8 N. gonorrhoeae isolates had extremely high MICs (>256 µg/mL) for azithromycin and MICs of 0.125–0.25 µg/mL for ceftriaxone and cefixime (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/23/5/17-0088-Techapp1.pdf). The 8 isolates,
which were collected from 7 patients and included 2 isolates (urethral and urine) from the same patient (GCWGS_0182 and GCWGS_0322), were sent to CDC for confirmatory testing using agar plate dilution (5).

All 61 N. gonorrhoeae isolates were sequenced (paired-end; 2 × 250-bp read length) on an Illumina MiSeq sequencer (Illumina Denmark ApS, Copenhagen, Denmark) at the HDOH State Laboratories Division. De novo assembly was conducted at CDC by using SPAdes 2.5.1 (http://www.cab.spbu.ru/software/spades), and the core genome single-nucleotide polymorphism alignment was generated by using Parsnp 1.2 (http://www.cbcb.umd.edu/software/harvest), with the FA19 genome (GenBank accession no. CP012026) as the reference. The maximum-likelihood phylogeny was reconstructed by using RAxML 8.0.0 (http://sco.h-its.org/exelixis/web/software/raxml) with 1,000 bootstrap replicates. Whole-genome sequencing data were also used to determine the multilocus sequence typing (MLST) and N. gonorrhoeae–multiantigen sequence typing (NG-MAST) allelic profiles for the targeted isolates.

Results of the phylogenetic analysis indicated that the 8 isolates were closely related and formed a single clade (Figure) with 223 single-nucleotide polymorphism differences. MLST analysis revealed 1 unique profile, sequence type (ST) 1901 (online Technical Appendix), which is a highly successful lineage associated with multidrug resistance that probably originated in Japan (6). The results of the NG-MAST analysis indicated that all 8 isolates shared 1 novel profile, ST14121. Epidemiologic investigations did not associate sexual network transmission among the 7 patients, although 2 patients reported sex with the same partner. However, the consistent MLST and NG-MAST profiles, in combination with the strongly supported clade, suggest the circulation of a single strain within the population.

To assess the contribution of known mutations to macrolide and cephalosporin resistance, we examined mutations in penA, ponA, mtrR, and 23S rRNA genes. Regarding azithromycin resistance, a deletion in the mtrR promoter associated with low-level resistance (7) and 4 mutated 23S rRNA copies with the A2059G mutation that confers high-level resistance (8) were identified in all 8 isolates. The ponA L421P mutation and mosaic penA alleles have been associated with reduced susceptibility to cephalosporins (7,9). The ponA L421P mutation was found in all 8 isolates; however, only the nonmosaic penA XVIII allele was detected.

The first N. gonorrhoeae isolate (H11S8) with high-level azithromycin resistance (HL-AziR) in the United States was identified in Hawaii in 2011 (10). More recently, Public Health England characterized 7 N. gonorrhoeae HL-AziR isolates that were collected in northern England during November 2014–March 2015 (11). Isolate H11S8 and those from England were more susceptible to ceftriaxone (MIC range 0.004–0.03 µg/mL) than the cluster of N. gonorrhoeae HL-AziR isolates identified in Hawaii. Genetic comparisons of the 2011 Hawaii isolate placed it in a distinct clade on the phylogenetic tree (Figure). The NG-MAST of H11S8 was ST649, and those from England were ST9768. Three HL-AziR N. gonorrhoeae strains were
isolated in 2011 and 2012 in Sweden with slightly higher ceftriaxone MICs (range 0.032–0.064 µg/mL) and were identified as either NG-MAST ST285 or ST8727 (12).

All patients infected with the HL-AziR isolates in our study were successfully treated with 250 mg ceftriaxone plus 1 g azithromycin. In contrast, a recent pharyngeal N. gonorrhoeae isolate, resistant to azithromycin and ceftriaxone, was recovered from a patient in the United Kingdom following treatment with dual antimicrobial therapy of 500 mg ceftriaxone plus 1 g azithromycin (13). Although the isolate was genetically distinct from the 8 isolates in Hawaii, it was more closely related to those 8 isolates than to the other 53 contemporary isolates from Hawaii.

Conclusions
The combination of ceftriaxone and azithromycin remains the hallmark for the treatment of gonorrhea worldwide on the basis of surveillance data that monitors antimicrobial susceptibility (2,14,15). Slight fluctuations have been observed in ceftriaxone MICs, but rarely have isolates been recovered with a MIC >0.5 µg/mL. However, a growing body of evidence suggests that azithromycin is becoming less effective and should not be used as a monotherapeutic agent for gonorrhea. The observation of increased MICs for ceftriaxone and azithromycin in a cluster of strains from Hawaii might be the harbinger that the effectiveness of current treatment options will be challenged. It is critical that countries expand systematic surveillance for drug-resistant N. gonorrhoeae and that laboratories maintain culture capacity to support rapid response activities to confirm suspected treatment failures and mitigate transmission through contact tracing. Expansion of laboratory capacity to conduct genetic analysis in real time would further benefit clinicians and sexually transmitted disease public health programs by identifying novel mechanisms of resistance that could be used to develop nonculture antimicrobial resistance tests and rapidly identify resistant N. gonorrhoeae strains in sexual networks.

Acknowledgments
We thank Kevin Pettus and Samera Sharpe for excellent technical assistance in testing the N. gonorrhoeae isolates for antimicrobial susceptibility.

Dr. Papp is a lead research microbiologist at the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. He is the senior author for CDC recommendations for the laboratory detection of Chlamydia trachomatis and Neisseria gonorrhoeae.

References

Address for correspondence: John R Papp, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E02, Atlanta, GA 30327-4027, USA; email: jwp6@cdc.gov; A. Christian Whelen, State Laboratories Division, Hawaii Department of Health, Pearl City, HI 96782, USA; email: chris.whelen@doh.hawaii.gov
Azithromycin Resistance and Decreased Ceftriaxone Susceptibility in *Neisseria gonorrhoeae*, Hawaii

Technical Appendix

**Technical Appendix Table.** Phenotypic antimicrobial susceptibility and genetic strain typing of *Neisseria gonorrhoeae* isolates with high-level resistance to azithromycin and decreased in vitro susceptibility to ceftriaxone, Hawaii

<table>
<thead>
<tr>
<th>Strain/SRA Accession Number</th>
<th>BLM*</th>
<th>Test type</th>
<th>Azithromycin</th>
<th>Cefixime</th>
<th>Ceftriaxone</th>
<th>Ciprofloxacin</th>
<th>Gentamicin</th>
<th>Penicillin</th>
<th>Tetracycline</th>
<th>NG-MAST</th>
<th>MLST</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCWGS_0156/SRR4048856</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R)</td>
<td>8</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0163/SRR4048864</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.06 (S)</td>
<td>0.06 (S)</td>
<td>8 (R)</td>
<td>4</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0169/SRR4048869</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R)</td>
<td>8</td>
<td>&gt;64 (R)</td>
<td>4 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0180/SRR4048880</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R)</td>
<td>8</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0181/SRR4048881</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.06 (S)</td>
<td>0.125 (DS)</td>
<td>16 (R)</td>
<td>8</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.25 (DS)</td>
<td>0.25 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0182/SRR4048882</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.06 (S)</td>
<td>0.03 (S)</td>
<td>16 (R)</td>
<td>4</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GCWGS_0322/SRR5259797</td>
<td>(+)</td>
<td>Agar dilution</td>
<td>&gt;16 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>16 (R)</td>
<td>8</td>
<td>&gt;64 (R)</td>
<td>2 (R)</td>
<td>ST14121</td>
<td>ST1901</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etest†</td>
<td>&gt;256 (R)</td>
<td>0.125 (DS)</td>
<td>0.125 (DS)</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Beta-lactamase
†Interpretative criteria for ciprofloxacin (Susceptible ≤0.06 µg/mL, Resistant ≥1.0 µg/mL), penicillin (Susceptible ≤0.06 µg/mL, Resistant ≥2.0 µg/mL) and tetracycline (Susceptible ≤0.25 µg/mL, Resistant ≥2.0 µg/mL), cefixime (Susceptible ≤0.25 µg/mL) and ceftriaxone (Susceptible ≤0.25 µg/mL) were in accordance with the Clinical Laboratory Standards Institute. The Gonococcal Isolate Surveillance Project’s alert values were used to interpret the MIC values for azithromycin (Susceptible ≤1.0 µg/mL, Resistant ≥2.0 µg/mL). The GISP alert criteria (Decreased susceptible ≥0.05 µg/mL) was also used for cefixime and ceftriaxone since CLSI does not report a resistant MIC value. There are no interpretative criteria for gentamicin. R refers to resistant, DS is decreased susceptible, S is susceptible and ND is not determined. ‡Etest MIC values are rounded up to the nearest doubling dilution for comparison to agar dilution results as recommended by the manufacturer.